The controversial KETO-CTA study, tough decisions in subclinical AF, and another potentially huge benefit for GLP-1 agonist drugs are discussed by John Mandrola, MD, in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I The KETO-CTA Study
- JACC Advances Paper: https://www.jacc.org/doi/10.1016/j.jacadv.2025.101686
- Meta-analysis https://doi.org/10.1016/j.ajcnut.2024.01.009
II Subclinical AF – Anticoagulate or Not?
Anticoagulation in Subclinical AF May Offer Little Benefit
https://www.medscape.com/viewarticle/anticoagulation-subclinical-af-may-offer-little-benefit-2025a1000b31
Treat AFib ‘Diagnosed’ by Smartwatch
https://www.medscape.com/viewarticle/treat-afib-diagnosed-smartwatch-2025a1000avp
- JAMA NO paper https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2833437
- NOAH https://www.nejm.org/doi/full/10.1056/NEJMoa2303062
- ARTESIA https://www.nejm.org/doi/full/10.1056/NEJMoa2310234
- McIntyre meta-analysis https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.123.067512
- Singer et al https://pmc.ncbi.nlm.nih.gov/articles/PMC2777526/
- Stroke paper https://www.ahajournals.org/doi/full/10.1161/STROKEAHA.123.045843
- American Journal of Medicine paper https://pubmed.ncbi.nlm.nih.gov/38331136/
III GLP1a for Treatment of Fatty Liver Disease
- ESSENCE trial https://www.nejm.org/doi/10.1056/NEJMoa2413258
Features
- CABG Still Superior to Stents Despite FAME 3 Endpoint Swap
https://www.medscape.com/viewarticle/cabg-still-superior-stents-despite-fame-3-endpoint-swap-2025a1000ao5
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
